The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Inclusion Criteria:

• Subjects with type 2 diabetes mellitus

• Glycosylated haemoglobin (HbA1c) 7.0-9.0% (53-75 mmol/mol) (both inclusive)

• Treatment with daily GLP-1 receptor agonist at maximum dose according to local label (i.e. 1.8 mg once daily (OD) Victoza® (liraglutide) or 10 microgram twice daily (BID)Byetta® (exenatide)) or documented maximum tolerated dose (i.e. 1.2 mg OD Victoza® (liraglutide) or 5 microgram BID Byetta® (exenatide)) in combination with a stabledaily dose of metformin (equal to or above 1500 mg or documented maximum tolerateddose) for 90 days or more prior to screening visit (Visit 1)

• BMI (body mass index) equal to or below 40 kg/m^2

Exclusion Criteria:

• Any use of oral anti-diabetic drugs (OADs) (except for metformin, pioglitazone andsulphonylurea) for 90 days or less prior to screening visit (Visit 1)

• Use of any drug (except metformin,pioglitazone, sulphonylurea and GLP-1 receptoragonist) which in the Investigator's opinion could interfere with the blood glucoselevel (e.g. systemic corticosteroids)

• Treatment with any insulin regimen (short term treatment due to intercurrent illnessincluding gestational diabetes is allowed at the discretion of the Investigator)

• Screening calcitonin equal to or above 50 ng/l

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrineneoplasia type 2 (MEN2)

• Cardiovascular disorders defined as: congestive heart failure (New York HeartAssociation (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebralstroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary, carotid or peripheral artery revascularisationprocedures

• Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema)according to the Investigator's opinion

• Subjects with a clinically significant, active (during the past 12 months) disease ofthe gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetesmellitus), neurological, genitourinary or haematological system that in the opinion ofthe Investigator may confound the results of the trial or pose additional risk inadministering trial products

• History of chronic pancreatitis or idiopathic acute pancreatitis